New and experimental therapies for pulmonary hypertension.
Advances in the understanding of the molecular and cellular pathogeneses of PPH have led clinicians beyond simple pulmonary vasodilation as the only treatment for PPH and to a realization that what were previously believed to be irreversible vascular lesions may, in fact, be reversible. The development of agents that target the known endothelial and nonendothelial defects in patients with PPH is well underway. Clinicians are witnessing an exciting new era for physicians and patients dealing with this disease.
Channick
R N
RN
Department of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California, USA.
Rubin
L J
LJ
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000627:therapeutic use; D004730:Endothelium, Vascular / Q000502:physiology; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D009569:Nitric Oxide / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D014665:Vasodilator Agents; D009569:Nitric Oxide; C048081:beraprost; D011464:Epoprostenol; C427248:treprostinil